All In Biotech

Drug Trial Radar · NCT02711553

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer

Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 309 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

309

Actual

Start

May 19, 2016

Primary completion

Feb 16, 2018

Study completion Dec 2026

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Mar 17, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate the efficacy and safety of ramucirumab or merestinib or placebo plus cisplatin and gemcitabine in participants with advanced or metastatic biliary tract cancer.

Conditions

  • Biliary Tract Cancer
  • Metastatic Cancer
  • Advanced Cancer

Interventions

  • RamucirumabDrug

    Administered IV

  • MerestinibDrug

    Administered orally

  • CisplatinDrug

    Administered IV

  • GemcitabineDrug

    Administered IV

  • Placebo OralDrug

    Administered orally

  • Placebo IVDrug

    Administered IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: Randomization to Progressive Disease or Death from Any Cause (Up To 20 Months)

Locations

82 sites in 18 countries. Site status is shown where the registry gives one.

  • The University of Arizona Cancer Center

    Tucson, Arizona

  • UCSF Medical Center at Mission Bay

    San Francisco, California

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • University of Florida School of Medicine

    Gainesville, Florida

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Washington University Medical School

    City of Saint Peters, Missouri

  • Washington University Medical School

    Creve Coeur, Missouri

  • Washington University Medical School

    St Louis, Missouri

  • Washington University Medical School

    St Louis, Missouri

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Florida Cancer Specialists

    Nashville, Tennessee

  • Tennessee Oncology PLLC

    Nashville, Tennessee

  • Fundacion Favaloro

    Ciudad de Buenos Aires, Argentina

  • Fundación CORI para la Investigación y Prevención del Cáncer

    La Rioja, Argentina

  • Centro Polivalente de Asistencia e Inv. Clinica CER-San Juan

    San Juan, Argentina

  • Alexander Fleming

    CABA, BS, Argentina

  • Hospital de Gastroenterologia Udaondo

    Capital Federal, Buenos Aires, Argentina

  • Fundacion Ars Medica

    San Salvador de Jujuy, Jujuy Province, Argentina

  • Clinica Viedma

    Viedma, Río Negro Province, Argentina

  • Centro Medico San Roque

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Calvary Mater Newcastle

    Waratah, New South Wales, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Austin Health

    Heidelberg, Victoria, Australia

  • Universitätsklinikum Salzburg

    Salzburg, Austria

  • KH der Barmherzigen Brüder Wien

    Vienna, Austria

  • Landesklinikum Wr. Neustadt

    Wiener Neustadt, Lower Austria, Austria

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg

    Leuven, Belgium

  • Cliniques universitaires Saint-Luc

    Brussels, Brussels Capital, Belgium

  • Fakultni nemocnice Hradec Kralove

    Hradec Králové, Czechia

  • Fakultni Nemocnice v Motole

    Prague, Czechia

  • Masarykuv onkologicky ustav

    Brno, Brno-město, Czechia

  • Aarhus Universitetshospital, Aarhus Sygehus

    Aarhus C, Denmark

  • Odense Universitetshospital

    Odense C, Denmark

  • CHU de Besancon Hopital Jean Minjoz

    Besançon, France

  • Hôpital C. HURIEZ

    Lille, France

  • CHRU de Montpellier-Hopital St Eloi

    Montpellier, France

  • Centre Antoine-Lacassagne

    Nice, France

  • Gustave Roussy

    Villejuif, France

Showing 40 of 82 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.